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Background
Immunoglobulin replacement therapy is standard of care
for patients with primary humoral immunodeficiency
[1]. Compared with intravenous immunoglobulin
(IVIG), subcutaneous immunoglobulin (SCIG) offers
comparable efficacy, lower costs and reduced systemic
reactions [2,3]. However, little is known about effects on
quality of life when patients transition from IVIG to
SCIG. It was our objective to assess changes in quality
of life, mood, sleepiness and fatigue in patients transi-
tioning from IVIG to SCIG.
Methods
Adult patients with common variable immunodeficiency
or X-linked agammaglobulinemia transitioning from
IVIG to SCIG were invited to participate in this pro-
spective, open-label, pilot study. At least one set of
Short-Form 36 Health Survey (SF-36), Profile of Mood
States (POMS), Epworth Sleepiness Scale (ESS) and
nighttime sleep questionnaires was administered prior
to the final IVIG infusion. These were repeated monthly
for 3 months following the transition. Magnitude of
change was estimated between IVIG trough and final
SCIG steady-state data. Statistical significance was deter-
mined using linear mixed models for repeated measures
with Kenward-Rogers correction.
Results
Twenty-seven patients were included in the analysis. Two
of eight SF-36 quality of life domains showed significant
improvement: role limitations due to physical health (p =
0.01) and emotional problems (p = 0.04). Two of six
POMS mood subscales significantly improved: depression
(p = 0.03) and anger (p = 0.04). One of six POMS mood
subscales (tension, p = 0.08) and POMS total mood dis-
turbance scores (p = 0.09) trended towards improvement.
No significant changes were noted in ESS or nighttime
sleepiness scores.
Conclusions
Patients transitioning from IVIG to SCIG for treatment
of primary antibody immunodeficiency showed signifi-
cant improvement in several quality of life and mood
subscales. A larger study verifying these findings could
encourage patients to switch to SCIG self-administra-
tion, producing quality of life benefits while decreasing
health care costs.
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